Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle
Authors
Keywords
-
Journal
Vaccines
Volume 9, Issue 11, Pages 1347
Publisher
MDPI AG
Online
2021-11-18
DOI
10.3390/vaccines9111347
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Quadrivalent influenza nanoparticle vaccines induce broad protection
- (2021) Seyhan Boyoglu-Barnum et al. NATURE
- Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
- (2021) Brian J. Ward et al. NATURE MEDICINE
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
- (2020) Wanbo Tai et al. Cellular & Molecular Immunology
- A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
- (2020) Yan Wu et al. SCIENCE
- Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
- (2020) Katharine H. D. Crawford et al. Viruses-Basel
- A human monoclonal antibody blocking SARS-CoV-2 infection
- (2020) Chunyan Wang et al. Nature Communications
- Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
- (2020) Christopher O. Barnes et al. CELL
- COVID-19, SARS and MERS: are they closely related?
- (2020) N. Petrosillo et al. CLINICAL MICROBIOLOGY AND INFECTION
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials
- (2020) Brian J Ward et al. LANCET
- SARS-CoV-2 vaccines in development
- (2020) Florian Krammer NATURE
- Nanovaccine: A novel approach in immunization
- (2019) Seyed Mohammad Gheibi Hayat et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus
- (2019) Jessica Marcandalli et al. CELL
- Vaccine Evolution and Its Application to Fight Modern Threats
- (2019) Emanuele Andreano et al. Frontiers in Immunology
- RNA and Toll-Like Receptor 7 License the Generation of Superior Secondary Plasma Cells at Multiple Levels in a B Cell Intrinsic Fashion
- (2019) Caroline C. Krueger et al. Frontiers in Immunology
- Engineering a Rugged Nanoscaffold to Enhance Plug-and-Display Vaccination
- (2018) Theodora Ulli Jordanka Bruun et al. ACS Nano
- An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia
- (2018) Ahd A. Mansour et al. Frontiers in Microbiology
- Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine
- (2018) Fan Luo et al. VIROLOGICA SINICA
- Major findings and recent advances in virus–like particle (VLP)-based vaccines
- (2017) Mona O. Mohsen et al. SEMINARS IN IMMUNOLOGY
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology
- (2017) Rudragouda Channappanavar et al. Seminars in Immunopathology
- Synthetic plant virology for nanobiotechnology and nanomedicine
- (2017) John F. C. Steele et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague
- (2016) Paul M. Arnaboldi et al. VACCINE
- Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System
- (2015) Sukalyani Banik et al. PLoS One
- Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children
- (2014) John Lusingu et al. PLoS One
- Tobacco mosaic virus efficiently targets DC uptake, activation and antigen-specific T cell responses in vivo
- (2014) Jan Ole Kemnade et al. VACCINE
- Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge
- (2013) Jyothi K Mallajosyula et al. Human Vaccines & Immunotherapeutics
- Vaccine delivery using nanoparticles
- (2013) Anthony E. Gregory et al. Frontiers in Cellular and Infection Microbiology
- Correction: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
- (2012) Chien-Te Tseng et al. PLoS One
- Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent Fc R Pathway
- (2011) M. Jaume et al. JOURNAL OF VIROLOGY
- Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial
- (2011) Ally Olotu et al. LANCET INFECTIOUS DISEASES
- Polymeric human Fc-fusion proteins with modified effector functions
- (2011) David N. A. Mekhaiel et al. Scientific Reports
- Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity
- (2009) Lanying Du et al. VIROLOGY
- Genetically engineered Tobacco mosaic virus as nanoparticle vaccines
- (2008) Alison A McCormick et al. Expert Review of Vaccines
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started